Allergy Therapeutics, a biopharma company specializing in immunology based in West Sussex, UK, has initiated a study at Imperial College London to evaluate its virus-like particle (VLP) based peanut allergy vaccine candidate.
The study will employ human samples and molecular biomarkers to help establish the starting dose of its vaccine candidate for a subsequent first in-human phase I study.
The study will also serve as an early predictor of the efficacy of the company’s VLP platform as well as generate data to support a possible future investigational new drug (IND) application with the FDA and other authorities.
Said Manuel Llobet, CEO of Allergy Therapeutics:
A safe and effective short-course peanut allergy vaccine would be a significant breakthrough product, offering life-changing benefits to sufferers affected by this condition. The data we have generated so far for our peanut vaccine candidate give us confidence in its potential and through this study we have an opportunity to build on that confidence and provide our upcoming Phase I study with the greatest chances of success.
Our collaboration with Imperial College London, who are one of the foremost experts in this field, will equip us with a greater depth of knowledge of allergy biomarkers and their relationship to clinical outcomes, which will be applied to future clinical trials and aid in the development of our allergy immunotherapy pipeline.
The company’s platform has already undergone pre-clinical studies suggesting sustained immunity and protection against peanut anaphylaxis after a single vaccination.
